| Name | Title | Contact Details |
|---|---|---|
Bob Speakman |
Vice President, Chief Technology Officer | Profile |
Raydian Properties is passionate about creating a better Elder Living experience — the kind we want for our families. We are proud to be NJ’s largest provider of small group home dementia and Alzheimer’s care. We believe there is life beyond a diagnosis and with the right team, our residents can continue having a meaningful journey of a life worth living. Our homes welcome the flow of life with open kitchen, dining, and living spaces. Everyone who works at Raydian Properties is a Care Partner. We believe fresh, wholesome food nourishes both the mind and body. Care Partners prepare all food on-site and we believe in empowering every Care Partner to create joyful living experiences.
Hatten Holdings is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of prescription medicines for pets in the United States and Europe. It develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a potent and selective ghrelin agonist for the stimulation of appetite in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension to manage post-operative pain in cats and dogs following surgery. The company was founded in 2010 and is headquartered in Kansas City, Kansas.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
ParkMed Urgent Care Center is a Alcoa, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.